Effectiveness of Postprandial Humalog in Toddlers With Diabetes

Ks, Rutledge; Hp, Chase; Gj, Klingensmith; Pa, Walravens; Rh, Slover; Sk, Garg

doi:10.1542/peds.100.6.968

Cited by 84 publications

(56 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the U.S. Food and Drug Administration initially approved Humalog only for children older than 12 years of age and adults, we and most others began using it in patients of all ages (19,20). Humalog was particularly helpful in children younger than 5 years of age with variable appetites.…”

Section: Methodsmentioning

confidence: 99%

The Impact of the Diabetes Control and Complications Trial and Humalog Insulin on Glycohemoglobin Levels and Severe Hypoglycemia in Type 1 Diabetes

et al. 2001

Self Cite

View full text Add to dashboard Cite

OBJECTIVE—This study was performed to determine the effects of the Diabetes Control and Complications Trial (DCCT) report in 1993 and the introduction of Lispro (Humalog) insulin in 1996 on glycemic control and on the number of severe hypoglycemic episodes in type 1 diabetic patients of various ages. RESEARCH DESIGN AND METHODS—Diabetes care parameters and HbA1c data from 884 subjects with type 1 diabetes were entered into our database at the time of clinic visits from 1993 through 1998. In addition, a questionnaire was sent to all patients to validate the number of insulin injections per day, the incidence of severe hypoglycemic episodes (as defined by the DCCT), and the use of Humalog insulin. Data were divided into four age-groups: <5, 5–12, 13–18, and >18 years of age. RESULTS—Longitudinal HbA1c levels declined significantly after the DCCT report in 1993–1996 (P < 0.001), but the number of severe hypoglycemic events increased (P < 0.001). A second decline in HbA1c levels was observed after the introduction of Humalog insulin in 1996 (P < 0.001). However, severe hypoglycemic episodes did not change (P = 0.26). CONCLUSIONS—Administration of Humalog resulted in an additional reduction in HbA1c levels beyond the reduction in HbA1c values after the DCCT report. In contrast to the increase in severe hypoglycemic events after the DCCT results, the number of severe hypoglycemic episodes did not increase after the introduction of Humalog, despite a further decrease in HbA1c values.

show abstract

Section: Methodsmentioning

confidence: 99%

The Impact of the Diabetes Control and Complications Trial and Humalog Insulin on Glycohemoglobin Levels and Severe Hypoglycemia in Type 1 Diabetes

et al. 2001

Self Cite

View full text Add to dashboard Cite

show abstract

“…Studies have demonstrated the feasibility of administering lispro insulin after meals in very young children (64). Dosing with lispro after meals allows a care provider to more accurately titrate the insulin doses for an erratic eater, with the goal of matching actual food intake and insulin more closely and minimizing the potential for hypoglycemia.…”

Section: Basal Bolus Insulin Regimensmentioning

confidence: 99%

Care of Children and Adolescents With Type 1 Diabetes

Klingensmith²,

et al. 2005

View full text Add to dashboard Cite

“…The better postprandial glycaemic control after a carbohydrate-rich meal with lispro compared with regular human insulin [85], as well as the more convenient mealtime or postprandial injection, make use of lispro attractive in children [86,87]. Type I diabetic children, however, lose residual endogenous insulin secretion faster than adult patients [88].…”

Section: Reviewmentioning

confidence: 99%